Macquarie University, Sydney Macquarie University ResearchOnline

Showing items 1 - 7 of 7.

Add to Quick Collection   All 7 Results

  • First
  • Previous
  • 1
  • Next
  • Last
Sort:
 Add All Items to Quick Collection
Date: 2016
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1183579
Description: The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and radiotherapy (RT). We sought to review clinic ... More
Reviewed: Reviewed
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1109683
Description: 1 page(s)
Reviewed: Reviewed
Date: 2016
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1111846
Description: 1 page(s)
Date: 2015
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114219
Description: 1 page(s)
Date: 2015
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1047547
Description: Background: Ipilimumab (Yervoy; Bristol-Myers Squibb) is a novel fully humanised monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4, an immune checkpoint molecule, to augment anti-tumour ... More
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1110399
Description: background: The prognostic significance of BRAF and NRAS mutations in metastatic melanoma patients remains uncertain, with several studies reporting conflicting results, often biased by the inclusion ... More
Full Text: Full Text
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1114316
Description: Background: Anti-PD-1 therapy has demonstrated activity in MM however current data may not fully reflect patterns of response and relapse as discerned by comprehensive lesion-specific analysis. Method ... More
Reviewed: Reviewed
  • First
  • Previous
  • 1
  • Next
  • Last